Similarly, midostaurin, a multi-kinase FLT3 inhibitor approved for combination with induction chemotherapy for newly diagnosed FLT3 mutated AML, was associated with QT prolongation (13%), leading to dose modification or treatment discontinuation [8]. Here, FLT3 is linked to acute myeloid leukemia.